


## CLAIMS

I Claim:

1) A process for inhibiting NF- $\kappa$ B in a mammalian cell in which NF- $\kappa$ B has been activated by an agency external to said cell which comprises administering to the mammal in whose cells NF- $\kappa$ B has been activated an NF- $\kappa$ B inhibiting amount of a drug represented by the formula:



wherein n is 2-5, m is 0 or 1, R is NH<sub>2</sub>, NHOH, OC<sub>1-3</sub> alkyl, or O-phenyl, R' is 0-phenyl, R is 0, NH or NOH, R'' is H or OH and pharmaceutically-acceptable acid-addition <sup>salt</sup> and acylated phenol derivatives thereof.

G C, E 2) A process according to Claim 1 in which the external agency activating NF- $\kappa$ B is an inflammatory process <sup>in</sup> <sup>comprising</sup> <sup>includes, but is not</sup> <sup>limited to</sup> a cytokine, an activator of protein kinase B, a virus or an oxidant.

HEBVR-5

G 3) A process according to claim <sup>14</sup> in which the external agency activating NF- $\kappa$ B is a drug or radiation administered to the host mammal in a chemotherapeutic process used in the treatment of cancer.

G 4) A process according to Claim <sup>14</sup> in which the administered NF- $\kappa$ B inhibitor is a free-radical scavenger.

G 5) A therapeutic process according to Claim <sup>14</sup> in which the NF- $\kappa$ B inhibitor is N,3,4-trihydroxybenzamide.

G 6) A therapeutic process according to Claim <sup>14</sup> in which the NF- $\kappa$ B inhibitor is N,3,4,5-tetrahydroxybenzamide.

G 7) A therapeutic process according to Claim <sup>14</sup> in which the NF- $\kappa$ B inhibitor is N,3,4-tetrahydrobenzimidamide.

G 8) A therapeutic process according to Claim <sup>14</sup> in which the NF- $\kappa$ B inhibitor is a ribonucleotide reductase inhibitor.

Add A' > Add F